Given that IMU’s success indeed all biotechs success at the end of the day is determined by the data and that a particular poster is already attacking today’s announcement it is reasonable to note:
1. Seven end of life patients have been treated.
2. Four have now shown a Complete Response.
3. Two have now shown Stable Disease.
4. One sadly has shown disease progression.
On any view of these outcomes OVER 85 Percent of the patients treated with AZERCel in this cohort have had a significant benefit.
If I personally was sitting in God’s waiting room and my Doctor offered me these odds on at least stabilising my cancers progression with an almost 60 percent chance of complete response I know what I would say. Yes please Doctor.
What about you?
My opinion only DYOR
Fact Finder
IMU Price at posting:
4.2¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)